A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Scientific Reports

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Anesthesiology And Pain Medicine

Show all topics

DOI

10.1038/s41598-024-79781-6

License

CC-BY-NC-ND

Other Formats

PDF